ANNEX IV

Model health certificate for import of ova and embryos of the ovine and caprine species

COUNTRY **Veterinary certificate to EU**

Part I: Details of dispatched consignment

I.1. Consignor Name Address Tel.		I.2. Certificate reference number	I.2.a
		I.3. Central Competent Authority	
		I.4. Local Competent Authority	
I.5. Consignee Name Address Postal code Tel.		I.6. Person responsible for the load in EU Name Address Postal code Tel.	
I.7. Country of origin ISO code	I.8. Region of origin Code	I.9. Country of destination ISO code	I.10. Region of destination Code
I.11. Place of origin Name Approval number Address Name Approval number Address Name Approval number Address		I.12. Place of destination Name Address Postal code	
I.13. Place of loading		I.14. Date of departure	
I.15. Means of transport Aeroplane ☐ Ship ☐ Railway wagon ☐ Road vehicle ☐ Other ☐ Identification: Documentary references:		I.16. Entry BIP in EU	
		I.17.	
I.18. Description of commodity		I.19. Commodity code (HS code) **05 11 99 90**	
		I.20. Quantity	
I.21.		I.22. Number of packages	
I.23. Identification of container/Seal number		I.24.	
I.25. Commodities certified for: Artificial reproduction ☐			
I.26. For transit through EU to third country ☐ Third country ISO code		I.27. For import or admission into EU ☐	

I.28. Identification of the commodities

Species (Scientific name)	Category	Identification mark	Approval number of the team	Quantity

COUNTRY **Ovine and caprine ova/embryos**

Part II: Certification

II. Health information	II.a. Certificate reference number	II.b.

I, the undersigned, official veterinarian, hereby certify that:

II.1. the exporting country .....
(name of exporting country) (2)

II.1.1. has been free from rinderpest, *peste des petits* ruminants, sheep and goat pox, contagious caprine pleuropneumonia, and Rift Valley fever during the 12 months immediately prior to collection of the ova/embryos (1) to be exported and up until its date of dispatch and no vaccination against these diseases took place during that period;

(1) either [II.1.2. has been free from foot-and-mouth disease during the 12 months immediately prior to collection of the ova/embryos (1) and did not carry out vaccination against foot-and-mouth disease during that period;]

(1) or [II.1.2. has not been free from foot and mouth disease during the 12 months immediately prior to collection of the ova/embryos (1) and/or carried out vaccination against foot-and-mouth disease during that period and the donor females come from holdings on which no animal was vaccinated against foot-and-mouth disease during 30 days prior to collection and no animal of susceptible species showed clinical signs of foot-and-mouth disease during the 30 days prior to, and at least 30 days after, the ova/embryos (1) were collected and the ova/embryos (1) were not subjected to penetration of *zona pellucida*;]

II.2. the ova/embryos (1) to be exported:

II.2.1. were collected and processed on premises within a 10-km radius of which there was no incidence of foot-and-mouth disease, vesicular stomatitis, Rift Valley fever in the 30 days immediately prior to their collection;

II.2.2. were stored at all times on approved premises within a 10-km radius of which there was no incidence of foot-and-mouth disease, vesicular stomatitis or Rift Valley fever from the time of their collection until 30 days thereafter;

II.3. the embryo collection team described under point I.11:

II.3.1. has been approved by the competent authority for export of ova/embryos (1) of the ovine and caprine species to the European Community;

II.3.2. carried out collection, processing, storing and transport of the ova/embryos (1) to be exported in accordance with Chapter III of Annex D to Directive 92/65/EEC;

II.3.3. is subject to inspection by an official veterinarian at least twice a year;

II.4. the donor females:

(1) either [II.4.1. were kept in a bluetongue virus-free country or zone for at least 60 days prior to, and during collection of the ova/embryos (1);]

(1) or [II.4.1. were kept during a bluetongue virus seasonally free period in a seasonally free zone;]

(1) or [II.4.1. were kept protected from the bluetongue virus competent vector *Culicoides* for at least 60 days prior to, and during the collection of the ova/embryos (1);]

(1) or [II.4.1. underwent a serological test to detect antibodies to the bluetongue virus group, carried out in accordance with the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals between 21 and 60 days after collection of the ova/embryos (1) and giving negative results;]

(1) or [II.4.1. underwent an agent identification test for bluetongue virus, carried out in accordance with the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals on a blood sample taken on the day of the ova/embryos (1) collection or the day of slaughtering and giving negative results;]

II.4.2. to the best of my knowledge and according to the written declaration made by the owner, do not come from holdings, and have not been in contact with animals of a holding, in which any of the following diseases have been clinically detected within the stated periods prior to collection of the ova/embryos (1) to be exported:

(a) contagious agalactia of sheep or goats (*Mycoplasma agalactiae, Mycoplasma capricolum, Mycoplasma mycoides* var. *mycoides* 'large colony'), within the last six months;

(b) paratuberculosis and caseous lymphadenitis, within the last 12 months;

(c) pulmonary adenomatosis, within the last three years; and

([1]) either [(d) Maedi/Visna for sheep or caprine viral arthritis/encephalitis for goats, within the last three years;]

([1]) or [(d) Maedi/Visna for sheep or caprine viral arthritis/encephalitis for goats, within the last 12 months, and all the infected animals were slaughtered and remaining animals subsequently reacted negatively to two tests carried out at least six months apart;]

II.4.3. are included in an official system for notification of diseases mentioned in point II.4.2;

II.4.4. showed no clinical signs of disease on the day of the ova/embryos ([1]) collection;

([1]) ([4]) either [II.4.5. originate from the territory described under point I.8, which has been recognised as officially brucellosis (*B. melitensis*)-free, and]

([1]) or [II.4.5. have belonged to a holding which has obtained and maintained its officially brucellosis (*B. melitensis*)-free status in accordance with Directive 91/68/EEC, and]

([1]) or [II.4.5. originate from a holding, where in respect of brucellosis *(B. melitensis)* all susceptible animals have been free from clinical or any signs of this disease for the last 12 months, none of the ovine and caprine animals have been vaccinated against this disease, save those vaccinated with Rev. 1 vaccine more than two years ago, and all ovine and caprine animals over six months of age have been subjected to at least two tests ([3]), carried out with negative results on samples taken on ..... *(date)* and on ..... *(date)* at least six months apart, the latter being within 30 days prior to collection of the ova/embryos ([1]), and]

have not been kept previously in a holding of a lower status;

([1]) either [II.4.6. have remained in the exporting country for at least the last six months prior to collection of the ova/embryos ([1]) to be exported;]

([1]) or [II.4.6. have remained in the exporting country for at least 30 days prior to collection of the ova/embryos ([1]) since entry into which they were imported from ..... ([2]) during the period of less than six months prior to collection of the ova/embryos ([1]) and satisfied the animal health conditions applying to donors of the ova/embryos ([1]) which are intended for export to the Community;]

II.5. The ova/embryos ([1]) to be exported:

([1]) either [II.5.1. were collected in the exporting country ([5]), which according to official findings is free from Akabane disease and Aino disease;]

([1]) or [II.5.1. were collected in the exporting country ([5]) and were not subjected to penetration of the *zona pellucida*, and the donor females underwent a serum neutralisation test for Akabane virus and Aino virus carried out on a blood sample taken not less than 21 days following their collection and giving negative results;]

([1]) either [II.5.2. were collected in the exporting country ([5]), which according to official findings is free from epizootic haemorrhagic disease (EHD);]

([1]) or [II.5.2. were collected in the exporting country ([5]) in which according to official findings the following serotypes of epizootic haemorrhagic disease (EHD) exist: ..... and were tested negative on two occasions not more than 12 months apart in an agar-gel immuno-diffusion test or competitive enzyme-linked immunosorbent assay ([6]) and a virus neutralisation test for all above-listed serotypes of EHD, carried out in approved laboratory on samples of blood taken prior to and not less than 21 days following collection of the ova/embryos ([1]);]

([1]) either [II.5.3. meet the requirements of Chapter A(I) of Annex VIII to Regulation (EC) No 999/2001;]

([1]) or [II.5.3. meet the requirements of Chapter A(I) of Annex VIII to Regulation (EC) No 999/2001and are destined for a Member States which benefits, for all or part of its territory, from the provisions laid down in points (b) or (c) of Chapter A(I) of Annex VIII to Regulation (EC) No 999/2001 and the donor animals comply regarding scrapie with the guarantees provided for by the programmes referred to in that point and with the guarantees ([7]) requested by the EU Member States of destination;]

II.6. The ova/embryos ([1]) to be exported

II.6.1. were collected after the date on which the embryo collection team was approved by the competent authority of the exporting country;

II.6.2. were processed and stored under approved conditions for at least 30 days immediately after their collection and transported under conditions which satisfy the terms laid down in Chapter III of Annex D to Directive 92/65/EEC;

II.7. The embryos were conceived by artificial insemination using semen coming from semen collection centres approved in accordance with Articles 11(2) and 17(3) respectively of Directive 92/65/EEC and located in a Member State of the European Community or in a third country listed in Annex I to Decision 2008/635/EC ([8]).

Notes

Part I

— Box reference I.8: Provide the code of territory as appearing in Annex III to Decision 2008/635/EC.

— Box reference I.11: place of origin shall correspond to the embryo collection team by which the ova/embryos were collected, processed and stored and listed in Annex III to Decision 2008/635/EC.

— Box reference I.22: number of packages shall correspond to the number of containers.

— Box reference I.23: identification of container and seal number shall be indicated.

— Box reference I.28: Species: select amongst *'Ovis aries'* and *'Capra hircus'* as appropriate.

Category: specify if (a) penetration or (b) non penetration of *zona pellucida*.

Identification mark shall correspond to the identification of the donor animals and the date of collection.

Approval number of the team: shall correspond to the embryo collection team of the ova/embryos origin listed in the Annex III to Decision 2008/635/EC.

Part II

([1]) Delete as appropriate.
([2]) Countries listed in Annex I to Decision 2008/635/EC.
([3]) Tests shall be carried out in accordance with Annex C to Directive 91/68/EEC.
([4]) Only for the territory appearing with the entry 'V' in column 6 of Part 1 of Annex I to Decision 79/542/EEC as last amended.
([5]) See remarks for exporting country concerned in Annex III to Decision 2008/635/EC.
([6]) Standards for EHD virus diagnostic tests are described in the Bluetongue Chapter of the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals.
([7]) Additional guarantees as laid down in Article 2 of Regulation (EC) No 546/2006.
([8]) Semen collection centres approved in accordance with EC legislation are listed on the Commission website: http://circa.europa.eu/irc/sanco/vets/info/data/semen/semen.html

— The signature and the stamp must be in a different colour to that of the printing.

Official veterinarian

Name (in capital letters): Qualification and title:

Date: Signature: